Anthony Bergmann Sells 25,000 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the sale, the chief financial officer owned 8,223 shares of the company’s stock, valued at $260,669.10. This trade represents a 75.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Anthony Bergmann also recently made the following trade(s):

• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00.

Capricor Therapeutics Stock Up 8.4%

NASDAQ CAPR traded up $2.59 during trading hours on Monday, reaching $33.50. 915,475 shares of the company were exchanged, compared to its average volume of 1,273,952. Capricor Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $40.37. The business’s 50 day simple moving average is $31.11 and its 200-day simple moving average is $22.76. The stock has a market capitalization of $1.94 billion, a P/E ratio of -14.82 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, sell-side analysts anticipate that Capricor Therapeutics, Inc. will post 0.01 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of CAPR. Goldman Sachs Group Inc. boosted its position in shares of Capricor Therapeutics by 39.5% in the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after acquiring an additional 116,373 shares during the period. Legal & General Group Plc lifted its position in Capricor Therapeutics by 8.4% during the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock valued at $410,000 after purchasing an additional 3,205 shares during the last quarter. Rhumbline Advisers lifted its position in Capricor Therapeutics by 7.3% during the second quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock valued at $531,000 after purchasing an additional 3,636 shares during the last quarter. Marshall Wace LLP bought a new stake in Capricor Therapeutics during the second quarter valued at approximately $796,000. Finally, Jump Financial LLC lifted its position in Capricor Therapeutics by 42.6% during the second quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock valued at $2,309,000 after purchasing an additional 69,515 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on CAPR shares. Piper Sandler reiterated an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, March 10th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Finally, B. Riley Financial lifted their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Capricor Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $46.09.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.